Showing Results for
- Academic Journals (34)
Search Results
- 34
Academic Journals
- 34
- Search Terms:
- 1From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedUse of myostatin inhibitors to increase muscle size and strength might be beneficial in musculoskeletal disorders. Haidet and colleagues showed that one-time gene administration of myostatin-inhibitor proteins--such as...
- 2From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedAbstract TWEAK is a multifunctional cytokine that controls many cellular activities including proliferation, migration, differentiation, apoptosis, angiogenesis and inflammation. TWEAK acts by binding to Fn14, a highly...
- 3From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedThe RIKEN Yokohama Institute Center for Genomic Medicine (CGM) and the NIH Pharmacogenetics Research Network (PGRN) have outlined their intention to establish a collaboration between US and Japanese scientists. The...
- 4From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedThe US FDA has released the draft details of how it intends to spend the annual $29.29 million allocated for 5 years to improve drug safety. The lowdown: When PDUFA IV was reauthorized through the FDA Amendments Act...
- 5From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedParasitic nematodes are an increasing threat to livestock and humans owing to the widespread development of resistance to the three major classes of anthelmintics: benzimidazoles, imidazothiazoles and macro cyclic...
- 6From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedIan Frazer--one of the scientists who created the VLP technology enabling the development of vaccines against human papillomavirus (HPV)--has been building up the Diamantina Institute since the late 1980s. "I decided...
- 7From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedThe past year has seen at least two major media flare-ups about pharmaceutical drugs. In February this year, claims that widely used antidepressants don't work hit the front pages of many national newspapers in the UK....
- 8From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedA century ago, syphilis was a major public health threat in Europe. But by the 1920s, this situation was improved dramatically by the successful introduction of the first antibacterial drugs to combat the disease. These...
- 9From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedAbstract | The first evidence of the existence of renin was presented over 100 years ago. However, the importance of renin and the renin-angiotensin system in the pathogenesis of cardiovascular disease was only fully...
- 10From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedIn February 2008, rilonacept (Arcalyst; Regeneron), an intedeukin 1 blocker, was approved by the US FDA for the treatment of a group of rare autoinflammatory diseases known as cryopyrin-associated periodic syndromes....
- 11From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedThe heart has the ability to adapt to increased stress by undergoing hypertrophy, but if sustained, heart failure may ensue. Now, two studies in the journal of Clinical Investigation show that the dietary compound...
- 12From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedTakeda continues its 2008 spending spree by acquiring Millennium Pharmaceuticals. The lowdown: In its biggest deal this year, Takeda has agreed to acquire Millennium for ~$8.8 billion. Millennium will become a...
- 13From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedTo investigate the mechanisms of a traditional Chinese medicine, Wang and colleagues analysed the active ingredients of the Realgar-Indigo naturails formula. At a cellular level, the combination of active ingredientswere...
- 14From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedNovartis is to acquire a 25% stake in the leading eye-care company Alcon. The lowdown: Novartis will acquire the minority stake in Alcon from majority stakeholder Nestle for $11 billion. Further to this, Novartis will...
- 15From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedA secreted endoglycosidase from Streptococcuspyogenes, En-io'S, has been demonstrated to rescue mice from established severe idiopathic thrombocytopenic purpura (ITP). Accumulating evidence indicates that...
- 16From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedOncogenic mutations in the BRAF gene (such as V600E) correlate with increased severity and decreased response to chemotherapy in several human tumours. Inhibition of oncogenic B-Raf kinase activity could therefore be of...
- 17From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedThe EU has approved Pradaxa for the prevention of venous thromboembolic events in adults following orthopaedic surgery. The lowdown: Boehringer Ingelheim has beaten competitors Bayer and Bristol-Myers Squibb (BMS) to...
- 18From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedChina was the fastest-growing pharmaceutical market in 2004, with growth rates of 28%, and is forecasted to be the world's largest by 2050 (REF. 1). Multinational pharmaceutical companies manufactured 40 of the top 50...
- 19From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedA US district court has decided that proposed changes to how US patents are filed, sought by the US Patent and Trademark Office (PTO), are unlawful. In an attempt to reduce its backlog of patent applications, the PTO...
- 20From: Nature Reviews Drug Discovery. (Vol. 7, Issue 5) Peer-ReviewedTumour cell metastasis involves cell migration through integrin-dependent pathways. Zijlstra and colleagues used an in tegrin-assocIated tetraspanin CD151-specific monoclonal antibody to promote cell immobility. The loss...